<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00173862</url>
  </required_header>
  <id_info>
    <org_study_id>155I1</org_study_id>
    <nct_id>NCT00173862</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC</brief_title>
  <official_title>A Phase II Study of Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced Transitional Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Gemcitabine plus Ifosfamind as&#xD;
      second line chemotherapy in advanced transitional cell carcinoma in terms of response rate&#xD;
      and overall survival .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cisplatin-based combination chemotherapy produces a response rate of 40-70% in TCC patients.&#xD;
      However, only less than 10% of the patients can achieve long-term remission. Until now, there&#xD;
      is no standard chemotherapy for cisplatin-failed TCC patients. Both gemcitabine and&#xD;
      ifosfamide have been identified to have response rates of 20% or more in pretreated TCC&#xD;
      patients. It is thus reasonable to combine these two active drugs as a second-line treatment&#xD;
      for TCC.&#xD;
&#xD;
      Patients enrolled must have a pathologically proven urothelial transitional cell carcinoma&#xD;
      (TCC) and must have exposed to one cisplatin-based combination chemotherapy for the advanced&#xD;
      disease. GI regimen will be continued until maximal response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2000~2006</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Safety</measure>
    <time_frame>2000~2006</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Transitional Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Ifosfamide</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed transitional cell carcinoma&#xD;
&#xD;
          -  Advanced / metastatic disease failed to prior chemotherapy (diagnostically confirmed&#xD;
             disease progression during the treatment of last chemotherapy or within 6 months after&#xD;
             the end of last chemotherapy)&#xD;
&#xD;
          -  Presence of at least one measurable disease which is defined as lesion that can be&#xD;
             measured in at least 1 dimension as ³ 20 mm with conventional technique or ³ 10 mm&#xD;
             with spiral CT scan&#xD;
&#xD;
          -  Performance status of ECOG 0, 1, 2&#xD;
&#xD;
          -  Age 20 years or older&#xD;
&#xD;
          -  Life expectancy more than 3 months&#xD;
&#xD;
          -  Adequate hematopoietic function as defined below:&#xD;
&#xD;
               -  WBC ³ 3,000/uL&#xD;
&#xD;
               -  Platelets ³ 75,000/Ul&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
               -  Total bilirubin £ 1.5 ´ ULN&#xD;
&#xD;
               -  ALT / AST£ 5 ´ ULN&#xD;
&#xD;
               -  Creatinine £ 1.5 mg/dL&#xD;
&#xD;
          -  Adequate serum electrolyte concentration:&#xD;
&#xD;
               -  4 mmol/L&lt;[K+] &lt;5.3 mmol/L&#xD;
&#xD;
               -  0.74 mmol/L&lt;[Mg2+] &lt;1.03 mmol/&#xD;
&#xD;
               -  2.02 mmol/L&lt;[Ca2+]&lt;2.60 mmol/L&#xD;
&#xD;
          -  Result of ECG assessment: QTC &lt; 460 msec&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received chemotherapy, radiotherapy, surgery, or other investigational drug within&#xD;
             4weeks prior to entering the study&#xD;
&#xD;
          -  Receiving other concurrent palliative chemotherapy, radiotherapy, hormonal therapy, or&#xD;
             other investigational drug except non-disease related conditions (e.g. insulin for&#xD;
             diabetes) during study period&#xD;
&#xD;
          -  Presence of CNS metastasis&#xD;
&#xD;
          -  Previous or current malignancy with the exception of curatively treated non- melanoma&#xD;
             skin cancer or cervical carcinoma in situ&#xD;
&#xD;
          -  Presence of serious concomitant illness which might be aggravated by study medication:&#xD;
&#xD;
               1. Uncontrolled infection (active serious infections that are not controlled by&#xD;
                  antibiotics)&#xD;
&#xD;
               2. Peripheral neuropathy grade 2 or higher (by NCI common toxicity criteria in&#xD;
                  sensory or motor neuropathy)&#xD;
&#xD;
               3. Clinically significant arrhythmia (electrocardiogram QTc greater than 500 msec)&#xD;
&#xD;
               4. Prior myocardial infarction or serious coronary arterial disease within the last&#xD;
                  12 months&#xD;
&#xD;
          -  Mental status is not fit for clinical trial.&#xD;
&#xD;
          -  Women of child-bearing potential (pregnancy or breast feeding)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hung Hsu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology , National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann-Lii Cheng, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology , National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>July 23, 2007</last_update_submitted>
  <last_update_submitted_qc>July 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2007</last_update_posted>
  <keyword>Combination, Chemotherapy,transitional cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

